The substantial dilution from this at-the-market-priced offering will likely pressure the stock near term as new shares enter the market. However, Lilly's continued strategic investment and 6-month lockup provide a partial offset. Monitor for any pipeline catalysts that could offset the dilution over the coming quarters.
Price Chart
Executive Summary
ProQR priced a $50.0 million underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share, alongside a concurrent $9.2 million private placement to strategic partner Eli Lilly at the same price. Net proceeds from the offering are approximately $46.5 million, and the total capital raise represents roughly 30% of the company's pre-offering market cap, resulting in significant dilution of about 25% for existing shareholders.
Key Facts
- Offering of 27,624,310 ordinary shares at $1.81 per share for gross proceeds of $50.0 million.
- Concurrent private placement to Eli Lilly of 5,100,780 shares at $1.81 for gross proceeds of approximately $9.2 million.
- Net proceeds from the offering alone are approximately $46.5 million after underwriting discounts and estimated expenses.
- Lilly's purchase maintains its pro rata beneficial ownership (15.59%) and is subject to a 6-month lockup.
- The offering represents approximately 25% dilution based on pre-offering outstanding shares of ~108.4 million.
- Proceeds will be used to fund research and clinical development of pipeline candidates and for general corporate purposes.
Financial Impact
Total gross proceeds of approximately $59.2 million from the offering and private placement; net proceeds from the offering are approximately $46.5 million. Dilution of ~25% to existing shareholders.
Risk Factors
- Significant shareholder dilution of approximately 25% from the offering.
- Potential near-term selling pressure as the new shares begin trading.
- Clinical-stage biotech risk with no approved products; capital raise extends runway but does not guarantee pipeline success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-077892 |
| Document: tm2618527d2_ex10-1.htm | 0001104659-26-077892 |
| Document: tm2618527d2_ex5-1.htm | 0001104659-26-077892 |
| Document: tm2618527d2_6k.htm | 0001104659-26-077892 |
| Document: tm2618527d2_ex99-1.htm | 0001104659-26-077892 |
| Document: 0001104659-26-077892-index-headers.html | 0001104659-26-077892 |
| Document: 0001104659-26-077892-index.html | 0001104659-26-077892 |
| Document: 0001104659-26-077892.txt | 0001104659-26-077892 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 6-K | $1.70 $1.66 | ▼ −2.35% | ▼ −1.68% | $1.30 (−23.24%) |
Sep 9, 2026 6w ago | 6-K | $1.99 $1.86 | ▼ −6.53% | ▼ −5.44% | $1.30 (−34.42%) |
Jul 16, 2026 14w ago | EFFECT | $1.67 $1.79 | ▼ −7.19% | ▼ −8.86% | $1.30 (+21.86%) |
Jun 25, 2026 17w ago | 6-K | $1.53 $1.81 | ▼ −18.30% | ▼ −16.13% | $1.30 (+14.71%) |
Jun 25, 2026 17w ago | 424B5 | $1.53 $1.81 | ▲ +18.30% | ▲ +16.13% | $1.30 (−14.71%) |
Jun 2, 2026 20w ago | 6-K | $1.47 $1.41 | ▼ −4.08% | ▼ −0.26% | $1.30 (−11.22%) |
May 12, 2026 24w ago | 6-K | $1.60 $1.51 | ▲ +5.63% | ▲ +5.70% | $1.30 (+18.44%) |
Apr 30, 2026 25w ago | 6-K | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.30 (−16.88%) |
Apr 30, 2026 25w ago | Press Release | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.30 (−16.88%) |
Apr 8, 2026 28w ago | 6-K | $1.98 $1.95 | ▼ −1.52% | ▼ −4.70% | $1.30 (−34.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers